Literature DB >> 22639078

Multiple ligand docking by Glide: implications for virtual second-site screening.

Márton Vass1, Ákos Tarcsay, György M Keserű.   

Abstract

Performance of Glide was evaluated in a sequential multiple ligand docking paradigm predicting the binding modes of 129 protein-ligand complexes crystallized with clusters of 2-6 cooperative ligands. Three sampling protocols (single precision-SP, extra precision-XP, and SP without scaling ligand atom radii-SP hard) combined with three different scoring functions (GlideScore, Emodel and Glide Energy) were tested. The effects of ligand number, docking order and druglikeness of ligands and closeness of the binding site were investigated. On average 36% of all structures were reproduced with RMSDs lower than 2 Å. Correctly docked structures reached 50% when docking druglike ligands into closed binding sites by the SP hard protocol. Cooperative binding to metabolic and transport proteins can dramatically alter pharmacokinetic parameters of drugs. Analyzing the cytochrome P450 subset the SP hard protocol with Emodel ranking reproduced two-thirds of the structures well. Multiple ligand binding is also exploited by the fragment linking approach in lead discovery settings. The HSP90 subset from real life fragment optimization programs revealed that Glide is able to reproduce the positions of multiple bound fragments if conserved water molecules are considered. These case studies assess the utility of Glide in sequential multiple docking applications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22639078     DOI: 10.1007/s10822-012-9578-6

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  55 in total

1.  Generation and evaluation of a CYP2C9 heteroactivation pharmacophore.

Authors:  Ann-Charlotte Egnell; Cecilia Eriksson; Nan Albertson; Brian Houston; Scott Boyer
Journal:  J Pharmacol Exp Ther       Date:  2003-10-13       Impact factor: 4.030

2.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening.

Authors:  Thomas A Halgren; Robert B Murphy; Richard A Friesner; Hege S Beard; Leah L Frye; W Thomas Pollard; Jay L Banks
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

3.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

4.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.

Authors:  Richard A Friesner; Robert B Murphy; Matthew P Repasky; Leah L Frye; Jeremy R Greenwood; Thomas A Halgren; Paul C Sanschagrin; Daniel T Mainz
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

5.  Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone.

Authors:  J M Hutzler; R F Frye; K R Korzekwa; R A Branch; S M Huang; T S Tracy
Journal:  Eur J Pharm Sci       Date:  2001-08       Impact factor: 4.384

6.  Structural mechanism of the simultaneous binding of two drugs to a multidrug-binding protein.

Authors:  Maria A Schumacher; Marshall C Miller; Richard G Brennan
Journal:  EMBO J       Date:  2004-07-15       Impact factor: 11.598

7.  Interaction of Mycobacterium tuberculosis CYP130 with heterocyclic arylamines.

Authors:  Larissa M Podust; Hugues Ouellet; Jens P von Kries; Paul R Ortiz de Montellano
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

8.  Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites.

Authors:  Verawan Uchaipichat; Aleksandra Galetin; J Brian Houston; Peter I Mackenzie; J Andrew Williams; John O Miners
Journal:  Mol Pharmacol       Date:  2008-07-22       Impact factor: 4.436

Review 9.  Cooperative properties of cytochromes P450.

Authors:  Ilia G Denisov; Daniel J Frank; Stephen G Sligar
Journal:  Pharmacol Ther       Date:  2009-06-23       Impact factor: 12.310

Review 10.  Cytochrome p450 and chemical toxicology.

Authors:  F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2007-12-06       Impact factor: 3.739

View more
  6 in total

Review 1.  Principles and Overview of Sampling Methods for Modeling Macromolecular Structure and Dynamics.

Authors:  Tatiana Maximova; Ryan Moffatt; Buyong Ma; Ruth Nussinov; Amarda Shehu
Journal:  PLoS Comput Biol       Date:  2016-04-28       Impact factor: 4.475

2.  Identification of Potential WSB1 Inhibitors by AlphaFold Modeling, Virtual Screening, and Molecular Dynamics Simulation Studies.

Authors:  Ye Weng; Chenghao Pan; Zheyuan Shen; Sikang Chen; Lei Xu; Xiaowu Dong; Jing Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-13       Impact factor: 2.650

Review 3.  Pharmacological potential of biogenic amine-polyamine interactions beyond neurotransmission.

Authors:  F Sánchez-Jiménez; M V Ruiz-Pérez; J L Urdiales; M A Medina
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

4.  Considerations of Protein Subpockets in Fragment-Based Drug Design.

Authors:  Matthew Bartolowits; V Jo Davisson
Journal:  Chem Biol Drug Des       Date:  2015-08-31       Impact factor: 2.817

5.  Using the multi-objective optimization replica exchange Monte Carlo enhanced sampling method for protein-small molecule docking.

Authors:  Hongrui Wang; Hongwei Liu; Leixin Cai; Caixia Wang; Qiang Lv
Journal:  BMC Bioinformatics       Date:  2017-07-10       Impact factor: 3.169

Review 6.  Synthetic biology for the directed evolution of protein biocatalysts: navigating sequence space intelligently.

Authors:  Andrew Currin; Neil Swainston; Philip J Day; Douglas B Kell
Journal:  Chem Soc Rev       Date:  2015-03-07       Impact factor: 54.564

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.